May 2016

Peachey & Co LLP acted for Oncimmune Holdings plc in a £11m (gross) private placing and admission of the company’s shares to trading on the AIM market of the London Stock Exchange, with a market capitalisation for the company on Admission of £66m.

Oncimmune is a leading cancer diagnostics company through its proprietary EarlyCDT technology platform, having launched its first product, EarlyCDT-Lung, which has the capacity to detect lung cancer up to 4 years earlier than other methods. Oncimmune was originally a spin-out from Nottingham University and has been a client of the firm for over 10 years.

back to news